A new versatile peptide-based size exclusion chromatography platform for global profiling and quantitation of candidate biomarkers in hepatocellular carcinoma specimens

PROTEOMICS ◽  
2011 ◽  
Vol 11 (10) ◽  
pp. 1976-1984 ◽  
Author(s):  
Hyoung-Joo Lee ◽  
Keun Na ◽  
Min-Seok Kwon ◽  
Taesung Park ◽  
Kyung Sik Kim ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Size Exclusion Chromatography ◽  
Size Exclusion ◽  
Exclusion Chromatography

scholarly journals Hepatocellular carcinoma diagnosis using a novel electrochemiluminescence immunoassay targeting serum IgM-free AIM

2022 ◽  
Author(s):  
Tomo Shimizu ◽  
Takashi Sawada ◽  
Tomohide Asai ◽  
Yuka Kanetsuki ◽  
Jiro Hirota ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Size Exclusion Chromatography ◽  
Alpha Fetoprotein ◽  
Size Exclusion ◽  
Receiver Operating Curve ◽  
Serum Samples ◽  
Alcoholic Fatty Liver ◽  
Number Of Patients ◽  
Exclusion Chromatography ◽  
Electrochemiluminescence Immunoassay

Abstract Background Recent increases in the number of patients with non-alcoholic steatohepatitis (NASH) warrant the identification of biomarkers for early detection of hepatocellular carcinoma (HCC) associated with NASH (NASH-HCC). IgM-free apoptosis inhibitor of macrophage (AIM), which generally associates with IgM in blood and exerts its biological function by dissociation from IgM, may serve as an effective biomarker for NASH-HCC. Here, we established a fully automatic and high-throughput electrochemiluminescence immunoassay (ECLIA) to measure IgM-free AIM and investigated its efficacy in diagnosing NASH-HCC and viral HCC. Methods IgM-free AIM levels were measured in 212 serum samples from patients with, or without, HCC related to NASH, hepatitis B virus, and hepatitis C virus, using ECLIA. We also developed an ECLIA for measuring both IgM-free and IgM-bound AIM and investigated the existing form of AIM in blood by size-exclusion chromatography. Results IgM-free AIM levels were significantly higher in the HCC group than in the non-HCC group, regardless of the associated pathogenesis. Moreover, the area under the receiver operating curve for IgM-free AIM was greater than that for conventional HCC biomarkers, alpha-fetoprotein or des-γ-carboxy prothrombin, regardless of the cancer stage. ECLIA counts of IgM-free AIM derived from samples fractionated by size-exclusion chromatography were significantly higher in patients with NASH-HCC than in healthy volunteers and in patients with non-alcoholic fatty liver and NASH. Conclusions Serum IgM-free AIM may represent a universal HCC diagnostic marker superior to alpha-fetoprotein or des-γ-carboxy prothrombin. Our newly established ECLIA could contribute to further clinical studies on AIM and in vitro HCC diagnosis.

Sign in / Sign up

Export Citation Format

Share Document